The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
(2019) European Urology — Vol. 75, n° 3, p. e51-e52 (2019)
Files
OSullivan-2019inpress-Thecaseagainst.pdf
Open Access - Adobe PDF
- 138.13 KB
Details
- Authors
- Abstract
- (en) We write regarding a recent label change recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) and implemented by the European Medicines Agency (EMA) for the bone-targeted agent radium-223 (Xofigo) [...]
- Affiliations
Citations
O’Sullivan, J. M., Heinrich, D., James, N. D., Nilsson, S., Ost, P., Parker, C. C., & Tombal, B. (2019). The Case Against the European Medicines Agency’s Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. European Urology, 75(3), e51-e52. https://doi.org/10.1016/j.eururo.2018.11.003 (Original work published 2019)